SUMMARY Clinical and biochemical effects of Gamma-vinyl-Gaba (GVG) have been evaluated in a blind video-controlled study in 10 psychiatric patients (mean age 71 yr) with tardive dyskinesia. CSF free and total Gaba and homocarnosine concentrations increased from three to five fold with GVG treatment. Despite the GVG-induced biological effects on Gaba metabolism, GVG did not consistently improve tardive dyskinesia. Psychomotor side-effects occurred in older patients, who only tolerated GVG dosages of 2-4 g/day.
Tardive dyskinesia, a neurological disorder of abnormal hyperkinetic movement, is a frequent side effect of chronic administration of neuroleptic treatment.1 It occurs in predisposed patients, in whom it may become a persistent problem for which no entirely satisfactory treatment is known.2 The pathophysiology of tardive dyskinesia has not been definitively elucidated but the most widely accepted hypothesis is the development of dopamine receptor hypersensitivity of the striatum following prolonged exposure to neuroleptics.' 3 In chronically neuroleptic treated laboratory animals, the coadministration of Gabaergic agonists has been shown to prevent the occurrence of apomorphine-induced stereotypes4 and to inhibit neuronal dopaminergic activity.' Therefore Gabaergic agonists might be effective agents to treat tardive dyskinesia in humans. Clinical trials using drugs with putative Gabaergic activity have produced mixed results. Thus, sodium valproate6 and baclofen7 have been claimed to be slightly beneficial. Muscimol8 and y-acetylenic Gaba9 were also moderately effective but at the expense of unacceptable side effects. THIP was ineffective in tardive dyskinesia, with high doses being poorly tolerated. '0 Gamma-vinyl Gaba (GVG), an enzyme-activated irreversible inhibitor of Gaba-transaminase, produces large increases in brain Gaba concentrations of laboratory animals.1' In addition, oral administration of GVG to man produces dose-related elevation of CSF Gaba content"2 probably reflecting increased brain Gaba levels.'3 In a pilot single blind study with tardive dyskinesia patients, the administration of GVG reduced the hyperkinesia scores of six of nine patients without producing major side effects. ' unchanged throughout the study. The study began with a 2 week placebo period, followed by a 6 week period of GVG, and a final 2 week placebo period during which the patients received the same daily number of tablets as during the last week of GVG treatment. GVG or placebo was given twice daily. The starting dose of GVG was 1 g/day, this dose being increased by 1 g/day each week, to a maximum of 6 g/day.
Should any dosage less than 6 g/day abolish all signs of tardive dyskinesia or be poorly tolerated, then that dose was maintained for the rest of the study.
Clinical evaluations
Symptoms of hyperkinesia and of Parkinsonism were recorded twice during the first week and then once weekly, with a videotape camera, at the same time of the day during a 10 minute standardised examination.'9 At the end of the study all tapes were examined by the same rater who was blind as to the treatments. The rating scale for tardive dyskinesia included the examination of 10 body regions, each scored 0 to 4 according to the severity of the symptoms. '9 The Parkinsonian symptoms were rated on 22 items also scored 0 to 4 for severity. '9 Biological evaluations Routine safety biological tests were performed during the initial placebo period and repeated on the last day of the active treatment period. Lumbar CSF was obtained from seven consenting patients at the end of the initial placebo period and the 6-week GVG period. CSF was drawn at 8:00 am from fasting patients in the supine position. The 5th to 10th millilitres of CSF were collected as one ml fractions into tubes kept in dry ice. Each sample was immediately frozen at -70°C until analysis. Free and total Gaba, homocarnosine and GVG were assayed as previously described.'2 Blood
Gaba and GVG concentrations were also analysed on the last day of the initial placebo period and once weekly during the GVG treatment period. (fig 2) . The increase of CSF free Gaba was proportional to the CSF GVG levels (fig 3) but did not correlate with oral treatment dosage. The elevations of free Gaba serum concentrations and CSF free Gaba concentrations were not related (p = 018). Standard laboratory data were not modified after GVG treatment.
Discussion
As no convenient long-term treatment is known for tardive dyskinesia using drugs acting on dopaminergic function, several studies have been performed with Gaba agonists.6`0 They produced mixed results ranging from no improvement'0 to mild improvement6 7 9 and in this last case9 the improvement was generally accompanied by an increase in Parkinsonism. GVG has been reported by several centres to reduce the hyperkinetic symptoms of patients with tardive dyskinesia. 4 -18 This beneficial effect was not confirmed in our placebo-controlled study. There is no obvious single explanation for this discrepancy, but when the patient population and the GVG regimen are compared across studies, several points can be mentioned. The lack of effect of GVG in our study cannot simply be due to problems of compliance. Not only was the administration of the medication carefully monitored, but the biological results also show that GVG was found in the patients' CSF and that CSF free Gaba concentrations increased proportionally to GVG CSF levels. The question of associated neuroleptic treatment was raised in a study9 where the positive effects of gamma-acetylenic Gaba correlated with the strength of concomitant neuroleptic treatment. In studies with GVG, however, improvement of tardive dyskinesia was observed independently from neuroleptic treatment. 16 18 In the present study half of the subjects were receiving neuroleptics, and their responses were not different from those patients not on neuroleptic treatment. The major difference between our study and those pre-L 
